Pancreatic Cancer Research

ResearcherUniversity of RochesterActive in the last 2 years

David C. Linehan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1859-2203; OpenAlex author ID A5074460989; NIH RePORTER profile ID 1896674. Sources: funder_awards.

Their work

Papers
41 (first author 1, last author 9)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
2
Collaborators
131
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: 4 papers · 2012: 4 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers, 1 grant · 2016: 2 papers, 1 grant · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 4 papers · 2023: 2 papers, 1 grant · 2024: 1 paper · 2025: 2 papers, 1 grant · 2026: 2 papers

Papers 41

  1. Improving Stereotactic Body Radiation Therapy by Rewiring Immunosuppressive Neutrophils in Murine Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2025.06.3853↗
  2. Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis. Co-author DOI 10.1080/2162402x.2026.2682058↗
  3. Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models. Co-author DOI 10.1136/jitc-2024-010820↗
  4. Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models. Co-author DOI 10.3390/cancers17020204↗
  5. Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer. Co-author DOI 10.1016/j.omtn.2024.102350↗
  6. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models. Co-author DOI 10.1136/jitc-2023-006842↗
  7. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  8. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer. Co-author DOI 10.1136/jitc-2022-004784↗
  9. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Co-author DOI 10.1158/1078-0432.ccr-21-2495↗
  10. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  11. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot. Last author DOI 10.1200/jco.21.02616↗
  12. Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting. Last author DOI 10.1002/jcsm.12699↗
  13. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  14. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Co-author DOI 10.1007/s10637-019-00830-3↗
  15. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1080/08820139.2020.1765795↗
  16. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
  17. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0373↗
  18. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  19. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  20. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Co-author DOI 10.1038/s41467-018-03600-6↗
  21. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Last author DOI 10.1136/gutjnl-2017-313738↗
  22. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Co-author DOI 10.1016/j.hpb.2017.01.012↗
  23. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  24. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Last author DOI 10.1016/s1470-2045(16)00078-4↗
  25. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pa… Co-author DOI 10.1097/coc.0000000000000003↗
  26. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  27. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/sla.0000000000000719↗
  28. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Last author DOI 10.1007/s00262-014-1527-x↗
  29. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Co-author DOI 10.1038/bjc.2014.224↗
  30. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Co-author DOI 10.1158/0008-5472.can-13-3723↗
  31. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Last author DOI 10.1158/1078-0432.ccr-13-0525↗
  32. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Co-author DOI 10.1371/journal.pone.0077243↗
  33. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4236/jct.2013.43096↗
  34. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Last author DOI 10.1001/archsurg.2012.1126↗
  35. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Co-author DOI 10.1007/s00262-011-1178-0↗
  36. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Co-author DOI 10.1634/theoncologist.2011-0268↗
  37. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/913↗
  38. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. First author DOI 10.1097/mpa.0b013e318215a9b1↗
  39. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Co-author DOI 10.1097/pas.0b013e318206c37a↗
  40. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0016958↗
  41. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Last author DOI 10.2174/156800911796191024↗

Trials 2

  1. Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer Principal investigator NCT00892242↗
  2. Chemotherapy and Radiation Following Pancreatic Surgery Principal investigator NCT00660270↗

Grants 4

  1. Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer R01CA262580↗
  2. Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity R01CA168863↗
  3. Targeting Macrophages to Improve Chemotherapy in Metastatic Pancreas Cancer AWARD pancan:2016-david-linehan-md-targeting-macrophages-to-improve-chemoth
  4. Targeting inflammatory monocytes in metastatic pancreas cancer AWARD pancan:2015-david-linehan-md-targeting-inflammatory-monocytes-in-meta

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bradley N. Mills · 8 shared papers, 2020–2026 · strength 1.28
  2. Scott A. Gerber · 7 shared papers, 2021–2026 · strength 1.24
  3. Angela L. Hughson · 6 shared papers, 2023–2026 · strength 1.19
  4. Tara G Vrooman · 6 shared papers, 2022–2026 · strength 1.08
  5. Scott Andrew Gerber · 1 shared grant, 2025 · strength 1.07
  6. Joseph D. Murphy · 7 shared papers, 2020–2026 · strength 1.00
  7. Jian Ye · 6 shared papers, 2020–2026 · strength 0.97
  8. Haoming Qiu · 4 shared papers, 2022–2026 · strength 0.76
  9. Richard Francis Dunne · 7 shared papers, 2017–2023 · strength 0.69
  10. Laura Maria Calvi · 3 shared papers, 2024–2026 · strength 0.57
  11. Brian Matthew Wolpin · 7 shared papers, 2017–2023 · strength 0.56
  12. Scott A. Gerber · 4 shared papers, 2020–2025 · strength 0.55
  13. William G. Hawkins · 11 shared papers, 2011–2018 · strength 0.50
  14. Daniel Tandel Chang · 7 shared papers, 2011–2023 · strength 0.50
  15. Albert C. Koong · 6 shared papers, 2017–2023 · strength 0.47
  16. Chen Yuan · 6 shared papers, 2017–2023 · strength 0.47
  17. Thomas E. Clancy · 6 shared papers, 2017–2023 · strength 0.47
  18. Douglas Adam Rubinson · 6 shared papers, 2017–2023 · strength 0.47
  19. Vicente Morales‐Oyarvide · 6 shared papers, 2017–2023 · strength 0.47
  20. Margaret M. Kozak · 6 shared papers, 2017–2023 · strength 0.47
  21. Aram F. Hezel · 6 shared papers, 2017–2023 · strength 0.47
  22. Jonathan Andrew Nowak · 6 shared papers, 2017–2023 · strength 0.47
  23. Andrea Wang‐Gillam · 12 shared papers, 2011–2016 · strength 0.44
  24. Andrew J. Aguirre · 5 shared papers, 2018–2023 · strength 0.42
  25. Booyeon Julia Han · 4 shared papers, 2018–2022 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.